BioTime (NYSEAMERICAN:BTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.
According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “
Separately, BidaskClub raised BioTime from a “sell” rating to a “hold” rating in a research note on Thursday, September 28th. Three investment analysts have rated the stock with a sell rating and two have given a buy rating to the stock. BioTime has a consensus rating of “Hold” and a consensus target price of $5.08.
A number of institutional investors have recently bought and sold shares of BTX. Voya Investment Management LLC boosted its stake in BioTime by 38.3% in the second quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 8,996 shares in the last quarter. Jane Street Group LLC boosted its stake in BioTime by 95.6% in the third quarter. Jane Street Group LLC now owns 44,548 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 21,778 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in BioTime in the second quarter worth $142,000. Moors & Cabot Inc. boosted its stake in BioTime by 25.2% in the second quarter. Moors & Cabot Inc. now owns 49,630 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 10,000 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in BioTime in the second quarter worth $180,000.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/12/biotime-btx-downgraded-by-zacks-investment-research-to-sell.html.
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.